+ T-cell counts >200 cells/mm 3 who initiate HAART for the prevention of motherto-child transmission, and discontinue after delivery. Methods: Clinical event rates after postpartum HAART discontinuation were calculated for all WHO stage 2-3 events, as well as for HIV progression warranting HAART re-initiation, defined by a WHO stage 4 event and/or CD4 is the standard of care; however, the effect of treatment discontinuation for these women has not been adequately evaluated.
In developed countries, use of HAART for prevention of mother-to-child transmission (MTCT) has reduced the rate of perinatal HIV infection to <2% [1] . In 2007, HIV prevalence in Brazil was approximately 700,000, with 30% of cases reported in women [2] . Since 2006, the Brazilian Ministry of Health HIV Guidelines have recommended HAART for the prevention of MTCT in all women, including those who do not meet criteria for treatment by current adult guidelines [3] . For those women receiving HAART solely for the prevention of MTCT, postpartum discontinuation of treatment is the standard of care; however, the effect of treatment discontinuation for these women has not been adequately evaluated.
In Strategies for Management of Antiretroviral Therapy (SMART), those who were antiretroviral therapy-naive at enrolment or off therapy for several months -a population similar to pregnant women likely to be initiated on HAART for prevention of MTCTexperienced inferior clinical outcomes with structured treatment interruption (TI). The hazard ratio for major cardiovascular, renal and hepatic disease was 1.7 (95%
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Jose H Pilotto 1, 2, 3 , Luciane S Velasque 1, 4 , Ruth K Friedman Introduction CI 1.1-2.5) for the group randomized to stop HAART compared to the continuous group, despite less overall antiretroviral (ARV) drug exposure in the interruption group [4] . Scheduled TI studies vary widely in inclusion criteria, interruption schedules and threshold for restarting therapy, thus making comparisons between studies and extrapolation to women receiving HAART for prevention of MTCT difficult. This study explores the virological, immunological and clinical outcomes in an urban cohort of HIV-infected pregnant women from Rio de Janeiro, Brazil, who received HAART solely for prevention of MTCT and discontinued therapy after delivery.
Methods
The HIV Family Care Clinic (HHFCC) operates within Hospital Geral de Nova Iguaçu (HGNI), the largest public hospital in an impoverished area adjacent to Rio de Janeiro. HHFCC is the main referral centre for HIVinfected patients and provides free ARVs and services for the prevention of MTCT. A prospective cohort of HIV-infected pregnant women has been followed at HHFCC since May 2005. Women were eligible for inclusion in the study if they were pregnant and had a positive HIV test. Inclusion for the present analysis was limited to the first pregnancy of ARV-naive women who had a baseline CD4 + T-cell count >200 cells/mm 3 and who delivered up to December 2007. Depending on point of entry, study visits occurred on a monthly basis until week 34 of pregnancy, and on a weekly basis thereafter until delivery. After delivery, women were evaluated at 2 and 4 weeks postpartum, and every 3 months thereafter for up to 3 years. According to Brazilian National HIV Guidelines, during the time interval under study, pregnant women with CD4 + T-cell counts >200 cells/mm 3 received HAART starting at 14 weeks of pregnancy and were taken off therapy immediately postpartum. Zidovudine and lamivudine were prescribed for all women in association with nevirapine, nelfinavir or ritonavir/lopinavir. Caesarean section was performed for women with viral load >1,000 copies/ml at the time of delivery. During follow-up, HAART was restarted according to Brazilian National HIV Guidelines, for a WHO stage 4 clinical event and/ or CD4 + T-cell count decrease to <200 cells/mm 3 . The CD4 + T-cell threshold changed during the time under study to allow providers to consider HAART initiation for patients with CD4
+ T-cell counts between 200 and 350 cells/mm 3 . At each maternal visit, a detailed medical history was collected and a complete physical examination was performed. Blood samples were drawn for CD4 + T-cell count (FACScan flow cytometer; Becton Dickinson, Mountain View, CA, USA), HIV RNA (NucliSens, Marcy-l'Étoile, France), complete blood count, hepatic function and renal function. The study was approved by the IPEC/ Fiocruz institutional Ethics Committee and written consent was obtained from all participants.
Statistical methods
The Wilcoxon signed-rank test was used to compare baseline CD4 + T-cell counts and HIV viral load with follow-up values 6 and 12 months after HAART discontinuation. Two separate incidence analyses were conducted: the first for the incidence of WHO stage 2-3 events after postpartum HAART discontinuation, and the second for the incidence of HIV disease progression, defined for the study cohort as a WHO stage 4 event or CD4 + T-cell decrease to <200 cells/mm 3 . Diagnoses of WHO clinical events were based on patient history, physician evaluation and laboratory findings [5] .
Predictors of the WHO stage 2-3 events and HIV progression outcomes were evaluated through Cox's proportional hazards models. We fitted an unadjusted model and selected all covariates statistically significant at 20%. Covariates that were statistically significant at 5% (P=0.05) were retained in the multivariate model. The assumption of proportionality in Cox's proportional hazard models were tested using Schoenfeld's residuals. Separate Kaplan-Meier plots were created for the development of WHO stage 2-3 events and HIV progression, with each plot stratified by baseline CD4 + T-cell count (200-499 cells/mm 3 and ≥500 cells/mm 3 ). Women were excluded from the Kaplan-Meier analysis from the point they experienced a WHO clinical event, went back on HAART or were lost to follow-up. The statistical analysis was performed using R software (version 2.7.2; The R Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 120 HIV-infected ARV-naive pregnant women with CD4 + T-cell counts >200 cells/mm 3 were started on HAART for the prevention of MTCT and discontinued therapy immediately after delivery. The median age was 25.0 years (IQR 21.2-29.6), 70% of the women were diagnosed with HIV during the current pregnancy and 68.3% were non-White, with the majority being mixed race. Two-thirds of participants had ≤8 years of formal education and more than one-half reported income of less than the Brazilian minimum wage per month. Cigarette smoking during pregnancy was reported by 26.3% of the women.
The median baseline CD4 + T-cell count was 518 cells/mm 3 (IQR 379-630, range 249-1,326) and median baseline HIV RNA 3.86 log 10 copies/ml (IQR 3.0-4.4). A total of 22% of women initiated therapy with a nevirapine-based HAART regimen, 72% with nelfinavir and 6% with lopinavir/ritonavir. HAART was modified in 9 (7.5%) women during pregnancy due to toxicity, and the majority of women changed from protease-inhibitor-to non-nucleoside reverse transcriptase inhibitor-based regimens. The most common toxicity was gastrointestinal. The median duration of HAART during pregnancy was 84 days (IQR 42.5-121.5). Table 1 summarizes key baseline characteristics of the cohort.
The median viral load reduction from HAART initiation to delivery was 3.62 log 10 copies/ml (IQR 0.47-5.23). Undetectable HIV RNA levels (<80 copies/ ml) were achieved by 61% of women, and 83.6% had HIV RNA levels <1,000 copies/ml at the time of delivery. Caesarean section and vaginal delivery rates were 62% and 32%, respectively. No cases of MTCT of HIV occurred in the cohort.
Postpartum HAART re-initiation
During study follow-up, 29 women resumed HAART after the initial postpartum discontinuation. Of those who resumed, 19 restarted for prevention of MTCT due to a subsequent pregnancy and the remaining 10 for HIV progression by the following criteria: 1 for a WHO stage 4 clinical event, 7 for CD4 + T-cell decrease to <200 cells/mm 3 
Immunological and virological outcomes after HAART discontinuation
The median CD4 + T-cell counts at delivery, 6 months and 12 months were 540 cells/mm 3 Table 2 .
HIV progression resulting in HAART re-initiation HIV progression requiring HAART re-initiation occurred in 10 women (incidence ratio 6/100 PY, 95% CI 3-11). The mean time from HAART discontinuation to HIV progression was 16 months (±sd 0.66). Of progressors, only one woman developed a WHO stage 4 event (disseminated tuberculosis). The remainder progressed with CD4 + T-cell decreases. A CD4 + T-cell decrease to <200 cells/mm 3 was observed in seven women. An additional two women were restarted on HAART for CD4 + T-cell decreases to <250 cells/mm 3 and 11% (7/64) of women with ≥500 cells/mm 3 . One woman had no baseline CD4 + T-cell count available and was excluded from this analysis. 
Predictors of WHO stage 2-3 clinical events and HIV progression after HAART discontinuation
Univariate and multivariate Cox proportional hazards regression was performed for both WHO 2-3 events as well as for HIV progression requiring HAART initiation. Covariates selected for multivariate models were educational level, household income, pre-HAART CD4 + T-cell count, HIV RNA at delivery and number of days on HAART. Lower baseline CD4 + T-cell count and shorter duration of HAART during pregnancy were significant predictors of WHO stage 2-3 events among ARV-naive women who had a baseline CD4 + T-cell count >200 cells/ mm 3 and discontinued HAART at delivery. Women who had baseline CD4 + T-cell counts between 200-500 cells/ mm 3 had a hazard ratio for WHO stage 2-3 events of 2.5 compared to women with baseline counts ≥500 cells/mm 
Discussion
Postpartum CD4 + T-cell count, viral load and clinical events after HAART discontinuation
Long-term outcomes are not well-defined among HIVinfected women with higher CD4 + T-cell counts for whom HAART is initiated to prevent MTCT. Pregnancy has been described as a state of immune activation, and this proinflammatory state appears to be more pronounced in the setting of HIV, with elevated proportions of activated CD8 + T-cells and increased levels of inflammatory markers that may remain above normal for 3-6 months postpartum [6, 7] . Based on this data, it appears reasonable to hypothesize that women taken off HAART postpartum may be subject to increased viral replication, disease complications and progression to AIDS. In this cohort of pregnant women there was no discernable effect of postpartum HAART discontinuation on viral load up to 12 months after delivery. Prior studies have shown an increase in HIV RNA levels at delivery and up to 12 weeks postpartum, specifically among those who received zidovudine monotherapy, combination nucleoside therapy or no ARVs [8] [9] [10] [11] . More recent studies from the HAART era have shown no increased risk of HIV progression during pregnancy [12] [13] [14] , and a single study from the US demonstrated that high rates of HAART use during pregnancy were independently associated with a decreased risk of HIV disease progression as defined by an AIDS-defining event or death [15] . An evidencebased postpartum HAART strategy remains elusive given these disparate findings.
In this cohort, HAART use during pregnancy was associated with increased CD4 + T-cell counts at 6 and 12 months after delivery, despite of postpartum HAART discontinuation. These data are consistent with another recent study from Brazil in pregnant women with CD4 + T-cell counts >300 cells/mm 3 on HAART for prevention of MTCT, in which it took a mean of 3.5 years for CD4 + T-cell counts to fall to <300 cells/mm 3 [16] . More durable immune reconstitution was found in those with higher baseline CD4 + T-cell count and greater CD4 + T-cell response to HAART during pregnancy, whereas more rapid CD4 + T-cell decrease was associated with prior ARV exposure and detectable viral load during prophylaxis.
In our cohort, WHO stage 2-3 events were common among postpartum women during follow-up, especially among those with baseline CD4 + T-cell counts 200-500 cells/mm 3 and shorter duration of HAART during pregnancy. In regions such as Brazil, where there is a high incidence of tuberculosis and serious bacterial infections, HAART continuation after delivery may decrease the risk of these events over the longer term. Additionally, bronchitis and sinusitis are frequent among HIV-infected individuals, particularly in developing countries, and these were common occurrences in this cohort in women stopping HAART postpartum. Although these illnesses are not typically serious, they cause discomfort for the patient, decrease the ability to provide care for children and result in lost income from days away from work. Our study is limited by the small sample size and relatively short follow-up over which to document clinical events and CD4 + T-cell count changes; however, because women were enrolled and followed at the same healthcare facility where they receive primary HIV and other medical care, it is unlikely that any important clinical events were missed among those staying in care. Overall, 13 women were lost to follow-up and we were unable to determine the status (regarding mortality) of these individuals. This is an important limitation of our study and could have biased our results, as women lost to follow-up may be more likely to have had serious clinical events and/or HIV progression.
Recently, the Brazilian National HIV Guidelines increased the threshold for HAART from 200 to 350 cells/mm 3 . This cohort had few women in the CD4 + T-cell strata between 200-350 cells/mm 3 and we were therefore unable to analyse specific risk in this group relative to the >350 cells/mm 3 group. In a recent study from Kenya, CD4 + T-cell count during pregnancy emerged as a significant predictor of mortality in HIV-infected pregnant women at 1 and 2 years postpartum, with all events in the first year occurring in women with CD4 + T-cell counts <350 cells/mm 3 , reinforcing the importance of the recent Brazilian HIV Guideline change [17] . In developed countries, HAART is routine for individuals with CD4 + T-cell counts <500 cells/mm 3 as a result of a number of recent observational studies, including the North American ACCORD cohort in which patients with CD4 + T-cell counts of >500 cells/mm 3 who deferred therapy until the CD4 + T-cell count fell below this threshold had a 94% increase in the risk of death compared to those who started HAART with >500 cells/mm 3 [18] . In Brazil and other developing countries, it is unlikely that treatment thresholds will be raised in response to this observational data; however, gathering additional data on CD4 + T-cell thresholds for initiation and continuation of HAART, to ensure that women remain healthy after pregnancy and delivery, should remain among the highest of priorities on the HIV research agenda.
Postpartum HAART discontinuation: is this type of structured treatment interruption harmful for women?
Structured TI in men and non-pregnant women has been evaluated in a number of studies. The aforementioned SMART trial randomized individuals to continuous HAART or to undergo TI when CD4 + T-cell counts increased to >350 cells/mm 3 after initiation of HAART [4] . This study showed that the risk of death, opportunistic diseases, and major cardiovascular, kidney and liver disease events were higher in the TI group compared to those who remained on continuous antiretroviral therapy. In the Trivican study, bacterial infections resulted in severe morbidity in the TI group and led to premature cessation of this arm [19] . Another recent large randomized clinical study of TI at CD4 + T-cell counts >350 cells/mm 3 revealed only a slightly increased risk of minor HIV-related complications in the interruption arm, more consistent with the findings of this cohort of pregnant women [20] . As compared to women using HAART for the prevention of MTCT, participants in TI trials are often older, have lower nadir CD4 + T-cell counts and are ARV-experienced, making extrapolation to HIV-infected pregnant women difficult and highlighting the importance of research in this population. Additionally, during the 1.5 years of follow up in our study, 19 of the 120 women had a subsequent pregnancy and resumed HAART for prevention of MTCT. These women are undergoing frequent TI during recurrent pregnancies, and may be subject to an increased risk of clinical events from this cycle of initiation and cessation of HAART. Enrolment in this cohort was limited to first pregnancies and therefore this study lacks long-term data on this important sub-group.
The natural history of HIV infection in postpartum women as well as the effect of treatment discontinuation in women started on HAART for prevention of MTCT has been reported from only a small number of studies. Data from the pre-HAART era in Zimbabwe described mortality as a function of CD4 + T-cell count among postpartum HIV-positive women, using HIV-negative postpartum women as the reference group. Mortality in postpartum women with CD4 + T-cell counts of 400-600 cells/mm 3 was 5.4× higher than in their HIV-negative postpartum counterparts. The majority of deaths among women with CD4 + T-cell counts >350 cells/mm 3 were due to tuberculosis (50%) and non-obstetric infectious diseases (24%) [21] . A US-based study evaluated treatment-naive women with CD4 + T-cell counts >350 cells/mm 3 initiated on ARVs during pregnancy, and evaluated clinical events and biomarkers within the first year after delivery among those stopping versus continuing therapy. Overall, the data did not indicate major differences in short-term outcomes, with the HR of a new class B event of 2.93 (95% CI 0.64-13.36) among those stopping combination therapy [22] . There were small numbers of women on three-drug HAART who discontinued therapy (18%), making comparisons with our cohort difficult. Another recent retrospective cohort study of postpartum women stopping versus continuing HAART showed a non-significant trend towards AIDS-defining events and death to be more common among women discontinuing HAART postpartum, but results were not statistically significant [23] . Of note, in this cohort, HAART continuers had baseline features associated with worse prognosis (including lower baseline CD4 + T-cell count and higher baseline viral load), yet had a trend toward lower risk of AIDS and non-AIDS events, suggesting benefit of HAART continuation among this group.
Conclusions
Current experience regarding HAART strategies for pregnant women with high CD4 + T-cell counts who initiate treatment for the prevention of MTCT is limited. Mounting data about the detriments of TI and the fact that many women go on to have additional pregnancies highlights the importance of further evaluating the risks and benefits of stopping therapy after pregnancy. Our findings support the benefit of raising the Brazilian treatment threshold from 200 to 350 cells/ mm 3 in protecting against WHO clinical events, and raise the question of utilizing a higher threshold, such as 500 cells/mm 3 , even in a resource-limited setting such as Brazil. Prospective randomized studies are necessary to better inform treatment guidelines in regard to postpartum HAART strategies that optimize longterm maternal health outcomes.
